What is the price target for ZYNE stock?
9 analysts have analysed ZYNE and the average price target is 1.28 USD. This implies a price decrease of -1.53% is expected in the next year compared to the current price of 1.3.
ZYNERBA PHARMACEUTICALS INC (ZYNE) Forecast, Price Target & Analyst Ratings
NASDAQ:ZYNE • US98986X1090
Current stock price
1.3 USD
+0.03 (+2.36%)
At close:
1.3015 USD
+0 (+0.12%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ZYNERBA PHARMACEUTICALS INC (ZYNE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Nov 13, 2023
- Period
- Q3 / 2023
- EPS Estimate
- $0.09
- Revenue Estimate
- 15.3M
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.28
Upside
-1.53%
From current price of $1.30 to mean target of $1.28, Based on 9 analyst forecasts
Low
$1.12
Median
$1.28
High
$1.47
Price Target Revisions
1 Month
0.00%
3 Months
-78.36%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for ZYNE. The average price target is 1.28 USD. This implies a price decrease of -1.53% is expected in the next year compared to the current price of 1.3.
The average price target has been revised downward by 78.36% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
48.89%
ZYNE was analyzed by 9 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about ZYNE.
In the previous month the buy percentage consensus was at a similar level.
ZYNE was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-08-16 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2023-08-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-06-23 | Canaccord Genuity | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Nov 13, 2023
- Period
- Q3 / 2023
- EPS Estimate
- $0.09
- Revenue Estimate
- 15.3M
- Revenue Q2Q
- N/A
- EPS Q2Q
- 145.90%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
99,900.00%
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
145.00%
Next Earnings Summary
ZYNE is expected to report earnings on 11/13/2023. The consensus EPS estimate for the next earnings is 0.09 USD and the consensus revenue estimate is 15.30M USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10K -96.43% | -100.00% | 90K | -100.00% | 11.475M | 48.855M 325.75% | 189.7M 288.29% | 372.12M 96.16% | 594.44M 59.74% | 877.79M 47.67% | 647.6M -26.22% | |||||
| EBITDA YoY % growth | -23.13M -85.04% | -32.73M -41.50% | -40.3M -23.13% | N/A 15.16% | -50.184M -51.65% | -39.372M 29.56% | -36.414M 4.08% | -44.778M -27.82% | -52.02M -16.17% | -34.578M 33.53% | -5.712M 83.48% | 70.584M 1,335.71% | 164.22M 132.66% | 268.77M 63.66% | 379.95M 41.37% | |
| EBIT YoY % growth | -23.21M -85.24% | -32.82M -41.40% | -40.4M -23.10% | -35.828M 15.05% | -52.911M -51.69% | -39.487M 29.37% | -36.763M 4.13% | -44.068M -25.01% | -53.531M -21.47% | -12.27M 77.08% | 92.274M 852.06% | 255.18M 176.55% | 923.4M 261.86% | 714.54M -22.62% | 377.91M -47.11% | |
| Operating Margin | -232,100.00% | N/A | -44,888.89% | N/A | N/A | N/A | N/A | N/A | -466.50% | -25.11% | 48.64% | 68.57% | 155.34% | 81.40% | 58.36% | |
| EPS YoY % growth | -2.56 -5.12% | -2.47 3.52% | -2.71 -9.72% | -1.57 31.00% | -1.95 -4.28% | -0.99 52.31% | -0.84 10.75% | -0.85 -2.82% | -0.64 25.00% | -0.37 41.57% | 0.53 240.45% | 1.60 204.85% | 2.88 79.94% | 3.28 13.98% | 4.20 27.95% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.09 145.90% | -0.22 -21.83% | -0.09 58.71% | 0.08 136.43% | -0.22 -344.44% | -0.26 -18.60% |
| Revenue Q2Q % growth | 15.3M | 7.65M | 15.3M | -100.00% | ||
| EBITDA Q2Q % growth | -11.424M -37.19% | -11.934M -40.95% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 3.834M 145.14% | -11.862M -36.57% | -5.284M 49.54% | 1.643M 114.75% | -13.671M -456.56% | -16.185M -36.44% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
15.71%
EPS Next 5 Year
31.48%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
1.94%
EBIT Next 5 Year
31.42%
ZYNERBA PHARMACEUTICALS INC / ZYNE Forecast FAQ
When does ZYNERBA PHARMACEUTICALS INC (ZYNE) report earnings?
ZYNERBA PHARMACEUTICALS INC (ZYNE) will report earnings on 2023-11-13, before the market open.
Can you provide the consensus estimates for ZYNERBA PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of ZYNERBA PHARMACEUTICALS INC (ZYNE) is 0.09 USD and the consensus revenue estimate is 15.30M USD.
What is the consensus rating for ZYNE stock?
The consensus rating for ZYNERBA PHARMACEUTICALS INC (ZYNE) is 48.8889 / 100 . This indicates that analysts generally have a neutral outlook on the stock.